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ABSTRACT
Objectives: The mortality associated with liver
disease continues to increase, despite the
improvements implemented in the UK healthcare as
does the prevalence of non-alcoholic fatty liver disease
(NAFLD), given the escalating prevalence of obesity.
The currently available methods to assess and monitor
the stage of liver disease present several limitations.
Recently, multiparametric MRI has been developed to
address these limitations. The aim of this study is to
develop a decision analytic model for patients with
suspected NAFLD, to investigate the effect of adding
multiparametric MRI to the diagnostic pathway.
Perspective: The model takes the perspective of the
UK National Health Service (NHS) as the service
provider.
Methods: A simple decision-tree model was
developed to compare the costs associated with 3
diagnostic pathways for NAFLD that use non-invasive
techniques. First, using transient elastography alone;
second, using multiparametric MRI as an adjunct to
transient elastography and third, multiparametric MRI
alone. The model was built to capture these clinical
pathways, and used to compare the expected
diagnostic outcomes and costs associated with each.
Results: The use of multiparametric MRI as an
adjunct to transient elastography, while increasing
screening costs, is predicted to reduce the number of
liver biopsies required by about 66%. Used as the sole
diagnostic scan, there remains an expected 16%
reduction in the number of biopsies required. There is
a small drop in the overall diagnostic accuracy, as in
the current model, liver biopsy is presumed to give a
definitive diagnosis.
Conclusions: The inclusion of multiparametric MRI,
either as an adjunct to or replacement of transient
elastography, in the diagnostic pathway of NAFLD may
lead to cost savings for the NHS if the model
presumptions hold. Further high-quality clinical
evidence and cost data are required to test the model’s
predictions.
INTRODUCTION
Liver disease refers to any disorder of the liver
that leads to a reduction in its functioning.
There are several types of liver disease, includ-
ing sequelae of hepatitis, alcoholic liver disease
(ALD) and non-alcoholic fatty liver disease
(NAFLD). ALD and NAFLD have similar
pathological spectra and disease may progress
through simple hepatic steatosis to steatohepa-
titis, cirrhosis and hepatocellular carcinoma.1 2
The clinical differentiation between ALD and
NAFLD is usually performed by taking a
history of a patient’s alcohol intake combined
with laboratory and imaging examinations.
Patients with non-alcoholic steatohepatitis
(NASH) usually exhibit more advanced fatty
degeneration of liver cells than those with alco-
holic steatohepatitis and the inﬂammatory
Strengths and limitations of this study
▪ This is the first study to evaluate the costs asso-
ciated with the inclusion of a new method to
assess liver disease in the diagnostic pathway of
patients with suspected non-alcoholic fatty liver
disease.
▪ Potential cost savings to the NHS have been
identified by the use of multiparametric MRI as
an adjunct to or replacement of transient elasto-
graphy if the model presumptions hold.
▪ The current decision analytic model compares
only the diagnostic pathways; it does not con-
sider the consequences of any diagnosis and
does not follow the progression of liver disease
in individuals.
▪ Additional high-quality clinical evidence and cost
data are necessary to develop and test the
model’s predictions further.
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inﬁltrate in NASH is somewhat less pronounced than in
alcoholic steatohepatitis.2
Improvements made in UK healthcare have resulted
in a decrease in mortality rates for most health condi-
tions, including heart disease, endocrine or metabolic
disease, respiratory disease and diabetes.3 Liver disease
is the exception. The standardised mortality rate has
increased by almost 500% since 1970 in patients younger
than 65 years.3 Liver disease accounts for 62 000 years of
working life lost every year; only ischaemic heart disease
(74 000 years) and self-harm (71 000 years) lead to a
greater premature loss of life.4
Between 1988 and 2008, the prevalence of chronic
liver disease caused by hepatitis B virus, hepatitis C virus
and ALD has remained stable.5 During the same period,
the prevalence of NAFLD increased from 5.51% to
11.01%.5 It is expected that the prevalence of NAFLD
will continue to increase, given the escalating prevalence
of obesity; with projections to the year 2030 estimating a
33% increase in obesity and a 130% increase in severe
obesity.6
Fatty liver (ie, simple steatosis) was believed to be a
benign condition with no or minimal rate of progres-
sion. However, recent evidence suggests that a substantial
proportion of patients (28–32%) with simple steatosis
progress towards NASH and ﬁbrosis within a 3 to 4-year
period.7–9 In most patients, NASH develops on a back-
ground of diabetes or impaired glucose tolerance in the
long term.10 Progression to cirrhosis, hepatocellular car-
cinoma and increased mortality has been reported for
patients with NASH.11 12
It is important, therefore, to detect fatty liver disease
at its early stages before progression into NASH, a cir-
rhotic stage or liver cancer. The early stages of NAFLD
can be managed and may regress if lifestyle advice is
provided and followed. Weight reduction has been
found to be associated with non-progressive disease.9
The early detection of NAFLD is important to establish
an effective course of treatment, and has the potential
to reduce the economic burden of liver disease and save
lives.13 Recent EASL–EASD–EASO clinical practice
guidelines have recommended that all individuals with
persistently abnormal liver enzymes or steatosis should
be screened for NAFLD.14
Liver biopsy
Liver biopsy is currently considered as the reference
standard for the diagnosis of liver disease. Liver biopsy is
nevertheless imperfect when used to assess the extent of
disease progression in terms of ﬁbrotic transformation
of liver tissue. This is because it allows examination of
only a very small area of the liver, potentially missing the
disease as changes within the liver can be patchy. In add-
ition, there is variability in histological interpretation
depending on the individual pathologist’s experi-
ence.15 16 Liver biopsy is invasive and associated with a
risk of haemorrhagic complications. It can also be
painful and stressful for the patient as well as time-
consuming. It is a relatively costly procedure and has a
low level of diagnostic performance for early stages of
ﬁbrosis.17 18 Liver biopsy may cause anxiety in patients,
and has been found to be painful in up to 30% of
cases.19 A recent willingness to pay evaluation found that
most patients (75%) who had undergone a liver biopsy
(publicly funded in British Columbia) would be willing
to self-pay for transient elastography (not publicly
funded in British Columbia).20 The majority of patients
preferred the non-invasive transient elastography
method, as it was associated with less discomfort during
and after the scan, and no feelings of anxiety after the
procedure was explained.20 Only those patients with
unknown liver disease were found to prefer liver biopsy.
There is a need in the diagnostic and monitoring
pathway for non-invasive methods to assess and monitor
the stage of liver disease.
Transient elastography
Transient elastography is a non-invasive method to assess
hepatic ﬁbrosis using ultrasound to measure the velocity
of an elastic shear wave transmitted through the liver
and assess liver stiffness.21 It is a painless test for which
sedation is not required, it is signiﬁcantly less expensive
than liver biopsy and it has not been associated with any
adverse treatment-effects.16 However, despite being
widely used, the cut-off values of liver stiffness for the
different stages of liver ﬁbrosis are not well established.22
Using transient elastography, signiﬁcant variations in
liver stiffness measurements related to operator and
patient factors rather than to disease progression have
been observed.23 The variations in cut-off values and
measurements limit the effectiveness of transient elasto-
graphy for monitoring and assessing the progression of
liver ﬁbrosis.23 In addition, transient elastography has a
high failure rate, particularly among obese patients. The
reported failure rates vary widely, ranging from 4.5% in
a cohort of patients with chronic liver disease24 to 41%
in a cohort of patients with BMI of 35 kg/m2 or higher.9
A 5-year prospective study of 13 369 examinations of
patients with suspected chronic liver disease reported an
average failure rate for transient elastography of
18.4%.25 The main factors inﬂuencing reliability were
limited operator experience and obesity, particularly
increased waist circumference. Subgroup analysis in this
study found the failure rate ranging from 12%
(BMI<25) to 53% (BMI>40).25 Failure rates for transient
elastography are higher for obese patients as the ultra-
sound wave used by the probe can be strongly attenu-
ated by fatty tissue.26 This limitation is important as
obese patients have an increased risk of liver disease
progression.
Multiparametric magnetic resonance imaging
Multiparametric magnetic resonance imaging (MRI) is a
new non-invasive technique designed to diagnose liver
ﬁbrosis. It consists of software (LiverMultiScan) that
enables the assessment of multiparametric liver data (ie,
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fat, iron and ﬁbrosis) based on an MRI scan. The ﬁrst
study on this technology reported an average scan time
of 23 min and demonstrated that multiparametric MRI
can quantify hepatic ﬁbrosis, iron and steatosis.27
Transverse abdominal T1 and T2* MR maps, corre-
sponding to segment 8 of the liver, are acquired.27 The
majority of percutaneous liver biopsies are taken from
this area. Once the image is acquired, an operator
deﬁnes a region of interest of the liver lobe, away from
vascular and biliary structures. The image is analysed
remotely, removing the need for interpretation by a radi-
ologist, potentially reducing the time needed for scan
results and costs. The software generates a report for the
clinician, with analyses of fat, iron and ﬁbrosis levels in
the liver. Multiparametric MRI has been included as the
only liver imaging test in the UK Biobank study.
Aim of the study
The aim of this study was to develop a preliminary deci-
sion analytic model of the diagnostic pathways for
patients with suspected NAFLD using two non-invasive
methods: (1) transient elastography and (2) multipara-
metric MRI. Such a model could indicate the potential
value of investment in further research and inform the
design of such research.
METHODS
Modelling methodology
A simple decision-tree model was constructed in Excel
to compare the costs associated with three diagnostic
pathways for NAFLD that use non-invasive techniques.
First, using transient elastography alone, then using mul-
tiparametric MRI as an adjunct to transient elastography
and ﬁnally, using multiparametric MRI alone (ﬁgure 1).
The chosen pathways were based on current clinical
practice according to clinical advice. The model was
built to capture these clinical pathways, and used to
compare the expected diagnostic outcomes and costs
associated with each.
For the base case model, it is presumed that the diag-
nostic pathways as set out in ﬁgure 1 are followed exactly
by all patients. In practice, these pathways, and the deci-
sion whether to take a liver biopsy at any stage, may vary
between individual patients depending on other indica-
tions or clinical opinion.
The ﬁrst patient pathway uses transient elastography as
the ﬁrst-line non-invasive diagnosis. Patients whose test
results are within the normal range are referred back to
their general practitioner and no further immediate
tests are carried out. Patients giving a positive test move
on to the next stage in the diagnostic pathway, which in
this case is a conﬁrmatory liver biopsy. Patients for
whom the test failed also move on to the next stage of
liver biopsy.
In the second pathway, multiparametric MRI is intro-
duced as a second line, non-invasive diagnostic tool for
those patients for whom the transient elastography
either gave a positive diagnosis or failed, and who would
otherwise have had a liver biopsy at this stage. For those
with a positive transient elastography, a further positive
diagnosis with multiparametric MRI is considered as
conﬁrmatory with no further tests necessary, whereas a
contradictory negative test or a failure results in a liver
biopsy. For those patients for whom the initial transient
elastography failed, multiparametric MRI becomes the
ﬁrst-line diagnosis whereby test outcomes are treated as
with transient elastography alone. That is, a normal
result requires no immediate further action, a positive
result would require a conﬁrmatory biopsy and a second
failure would be followed by a diagnostic biopsy.
In the ﬁnal pathway, multiparametric MRI replaces
transient elastography as the ﬁrst-line diagnostic tool
with test outcomes treated in the same way.
Model parameters
A hypothetical cohort of 1000 patients presenting with
suspected NAFLD was modelled. Initial clinical suspicion
would be based on laboratory ﬁndings and the absence
of other causes of liver disease. The estimated prevalence
for the successive stages of ﬁbrosis in the cohort was
taken from a recent Health Technology Assessment
(HTA).28 In their analysis, 48 studies were used to assess
the sensitivity and speciﬁcity of a number of diagnostic
tools at successive thresholds of liver ﬁbrosis. Overall
prevalence at each threshold was calculated from the
populations in the included studies. The median preva-
lence (minimum–maximum) of ﬁbrosis stages F1–F4 in
the studies identiﬁed, as well as additional model para-
meters, are presented in table 1. The median prevalence
at each threshold was taken to calculate prevalence for
each level of ﬁbrosis in the modelled population.
In the model, the sensitivity and speciﬁcity of transient
elastography at each threshold, as calculated in the
HTA, were used to predict the proportion of positive
and negative test results. For multiparametric MRI, sensi-
tivity and speciﬁcity for any level of ﬁbrosis were taken
from Banerjee et al.27 For those in the modelled cohort
with liver ﬁbrosis, the relevant sensitivities of the tests
were used to predict the rates for true positives and false
negatives, while for those without ﬁbrosis, the speciﬁci-
ties were used to predict the rates of false positives and
true negatives. Rates for test failures for multiparametric
MRI were provided by the manufacturer.
Costs
The model takes the perspective of the UK National
Health Service (NHS) as the service provider. The costs
for transient elastography and liver biopsy were derived
from the HTA report28 and inﬂated from 2012 to 2014
prices using the Personal Social Services Research Unit
inﬂator.29 A price for the multiparametric MRI proced-
ure is not currently available. For the base case analysis,
we presumed the cost of multiparametric MRI to be
the same as transient elastography. Cost-effectiveness
thresholds for multiparametric MRI were evaluated for
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each of the diagnostic pathways with this diagnosis
option. Probabilistic sensitivity analysis was conducted
using the sensitivity and speciﬁcity of transient elastogra-
phy. Given the short modelling horizon of the diagnostic
pathways, no costs were discounted.
RESULTS
Diagnostic pathway
Using transient elastography alone with the median
values for sensitivity and speciﬁcity, the model suggests
that for the cohort of 1000 patients with suspected
Figure 1 Decision analytic model of diagnostic pathways.
Table 1 Summary of model inputs
Model parameter Source
NAFLD prevalence
Fibrosis stage Median (minimum–maximum)
F1 0.588 (0.367–0.814) Crossan et al28
F2 0.319 (0.119–0.526)
F3 0.186 (0.050–0.440)
F4 0.128 (0.039–0.907)
Sensitivity of transient elastography for diagnosis of NAFLD
Fibrosis stage Summary sensitivity (95% CI)
F≥1 0.87 (0.81 to 0.92) Crossan et al28
F≥2 0.79 (0.72 to 0.85)
F≥3 0.82 (0.74 to 0.88)
F≥4 0.96 (0.83 to 0.99)
Specificity of transient elastography for diagnosis of NAFLD
Fibrosis stage Summary specificity (95% CI)
F≥1 0.76 (0.57 to 0.88) Crossan et al28
F≥2 0.76 (0.71 to 0.80)
F≥3 0.84 (0.78 to 0.89)
F≥4 0.89 (0.85 to 0.92)
Sensitivity of multiparametric MRI for diagnosis of NAFLD
Any fibrosis 0.86 Banerjee et al27
Specificity of multiparametric MRI for diagnosis of NAFLD
Any fibrosis 0.93 Banerjee et al27
Failure rates Base case (range)
Transient elastography 18.4% (12–50%) Castéra et al25
Multiparametric MRI 5% (2.5–10%) Manufacturer data
Costs
Transient elastography £52.44 Crossan et al28
Liver biopsy £983.70
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NAFLD, there would be 496 positive and 319 negative
test results. With 184 failures, 680 patients would move to
the next diagnostic level; which in this case is a liver
biopsy. Based on the prevalence of ﬁbrosis, and the speci-
ﬁcity of transient elastography, 64 patients with ﬁbrosis
would continue undiagnosed, giving a diagnostic accur-
acy for this pathway of 93.6% if liver biopsy is presumed
to give a deﬁnitive diagnosis. Introducing multipara-
metric MRI as a second-line diagnostic tool before liver
biopsy requires a further 680 multiparametric MRI tests
for those patients thus indicated, but is predicted to more
than halve the total number of liver biopsies required to
254. With the reduced number of biopsies, the overall
diagnostic accuracy falls to 91.6%, with 78 patients with
ﬁbrosis remaining undiagnosed and 5 patients without
ﬁbrosis receiving an incorrect positive diagnosis. Using
multiparametric MRI instead of transient elastography
would be expected to yield 508 positive and 442 negative
test results. With 50 failures, 558 liver biopsies would then
be indicated. The diagnostic accuracy for this pathway is
92.2%, with 78 undiagnosed cases of ﬁbrosis.
Cost analysis
For multiparametric MRI to be a cost-efﬁcient addition
in the diagnosis of NAFLD, any increase in costs asso-
ciated with its use, either as an adjunct to or instead of
transient elastography, needs to be compensated for by a
reduction in the number of biopsies needed. As a refer-
ence point, if multiparametric MRI were to cost the
same as transient elastography, that is, £52.44, the results
outlined above would give the cost outcomes as sum-
marised in table 2.
When using multiparametric MRI as an adjunct to
transient elastography, the cost of the expected extra
680 tests is more than offset by the savings made by the
reduction in the number of biopsies required. When
used instead of transient elastography, the cost of testing
remains the same, and there is some reduction in the
number of expected biopsies, due to a lower failure rate
and better diagnostic accuracy (mainly a better selectiv-
ity resulting in a lower rate of false positives).
Threshold and sensitivity analysis
The expected cost savings to be made in the two scen-
arios that use multiparametric MRI suggest that there is
an opportunity to increase the price. When used as a
second-line diagnosis after transient elastography, the
use of multiparametric MRI remains cost-effective up to
£616 per test. This ﬁgure reﬂects the potential cost
savings that could be made by performing these two
types of scans before considering a biopsy. When used as
the sole non-invasive diagnostic tool prior to liver biopsy,
multiparametric MRI remains a cost-effective replace-
ment for transient elastography up to a cost of £173 per
test. This ﬁgure is lower than the previous threshold as
in this scenario, there is again just one scanning method
used before a possible biopsy.
Probabilistic sensitivity analysis
The HTA report used the included studies to calculate
the sensitivity and speciﬁcity of transient elastography,
reporting mean values with 95% CIs.28 Probabilistic sam-
pling was performed on these distributions to assess the
robustness of the deterministic estimate of cost-
effectiveness when using transient elastography and mul-
tiparametric MRI in combination. The results of the
random sampling show an SD in the cost difference of
£42 per test, suggesting that there is a 95% probability of
this strategy remaining cost-effective up to a price thresh-
old of £547.
Threshold analysis
Setting the sensitivity and speciﬁcity of transient elasto-
graphy at the lower and upper 95% CIs gives break-even
prices for multiparametric MRI when used in conjunc-
tion with transient elastography of £558 and £659,
respectively. The price of multiparametric MRI therefore
needs to be reduced if the performance of transient
elastography is set to the most pessimistic levels. This is
because transient elastography gives an increase in the
proportion of positive results (from 41% to 53%) at this
lower diagnostic accuracy. These patients then go on to
multiparametric MRI and, as their transient elastography
results are less accurate, they are more likely to be con-
tradicted by multiparametric MRI. It is these patients
with contradictory results who then go on for a liver
biopsy. The model predicts that the percentage of the
original cohort in this category would rise from 9.5% at
the upper conﬁdence level to 18% at the lower conﬁ-
dence level. Thus, a more accurate transient
Table 2 Base case results
Transient elastography
Transient elastography
plus multiparametric
MRI Multiparametric MRI
Number Cost Number Cost Number Cost
Transient elastography tests 1000 £52 440 1000 £52 440 0 £0
Multiparametric MRI tests 0 £0 680 £35 684 1000 £52 440
Liver biopsies 679 £669 374 254 £249 902 558 £548 702
Total cost £721 814 £338 026 £601 142
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elastography means fewer contradictory results, with
fewer resultant biopsies. In the third treatment pathway
of multiparametric MRI alone, the corresponding break-
even costs are £203 for the lower CI, and £156 for the
upper CI.
Transient elastography and multiparametric MRI failure rate
Transient elastography and multiparametric MRI can fail
or give unreliable results. This is caused by patient
characteristics, technical issues with the equipment or
operator inexperience. As NAFLD is associated with
higher BMI, it might be expected that the failure rate for
transient elastography in NAFLD patients would be
higher than the 18.4% average reported in the Castéra
et al25 study. However, with a lack of evidence to quantify
any difference in average BMI of the two patient groups,
and the subsequent effect on transient elastography
failure rates, the ﬁgure of 18.4% was used in the model as
a conservative estimate of the baseline failure rate. For
multiparametric MRI, BMI is less of an issue, with
failures related more to technical issues. Trials by the
manufacturer have indicated a failure rate in the range of
∼2.5–5% associated with the use of multiparametric MRI.
With these ﬁgures in mind, tables 3 and 4 show an
illustrative range of failure rates for transient elastogra-
phy and multiparametric MRI, with the estimated break-
even cost of multiparametric MRI when used as an
adjunct to or replacement for transient elastography,
respectively.
In the ﬁrst scenario, as the failure rate of transient
elastography increases, a higher proportion of patients
move on to the second line diagnosis, with an associated
increase in the total number of biopsies. With the extra
cost of these biopsies, the break-even price of multipara-
metric MRI decreases. In the second scenario, as the
failure rate of transient elastography goes up, the break-
even price of multiparametric MRI also goes up, as it is
now replacing a decreasingly reliable transient elastogra-
phy. In both scenarios, the break-even price of multi-
parametric MRI decreases with increased failures, as any
extra failures at this stage mean extra liver biopsies.
Multiparametric MRI as the sole diagnostic test
For the third diagnostic pathway in ﬁgure 1, multipara-
metric MRI replaces transient elastography as the ﬁrst-
line diagnostic test. In the modelled base-case for this
scenario, as with transient elastography, patients receiv-
ing a positive diagnosis go on for a conﬁrmatory biopsy
to assess the nature and extent of any ﬁbrosis. If it can
be shown that multiparametric MRI is able to match the
diagnostic accuracy of liver biopsy in this role, then
there is the potential for it to replace biopsy as the
deﬁnitive diagnosis of liver ﬁbrosis. Incorporating this
possibility into the model reduces the number of biop-
sies by 508 per 1000 patients, the expected number of
positive multiparametric MRI tests; leaving biopsies for
just the 5% of patients for whom the multiparametric
MRI fails. Obviating the need for biopsies for those
patients with positive multiparametric MRI reduces the
total testing costs to 14% of those in the ﬁrst scenario of
transient elastography backed up with liver biopsy. This
means that the price of multiparametric MRI could
remain cost-effective up to a price of £672, if used as the
sole diagnostic test replacing the combination of transi-
ent elastography and liver biopsy. Removing biopsy as
the second-line test inevitably has an effect on the
overall diagnostic accuracy of this pathway, reducing the
rate of correct diagnoses to 89%, with 78 cases of ﬁbrosis
remaining undiagnosed and 27 patients without ﬁbrosis
receiving a false-positive test result.
DISCUSSION
This study proposes that the current NAFLD diagnostic
pathway may become more cost-efﬁcient with the inclu-
sion of multiparametric MRI either as an adjunct to or
replacement of transient elastography. The use of multi-
parametric MRI as an adjunct to transient elastography
has the potential to reduce the number of liver biopsies
by 66% while as a replacement would result in a
decrease in the number of biopsies needed of 16%. A
small drop in predicted diagnostic accuracy is predicted,
but this is inevitable because some biopsies are avoided,
and these are presumed, for our model, to be 100%
accurate. Acquisition of further clinical evidence is
required to conﬁrm whether the use of multiparametric
MRI as an adjunct to or replacement of transient elasto-
graphy can result in cost savings for the NHS. The
current study presents a preliminary decision analytic
model, which can be adapted and developed as more
evidence becomes available.
Given the increasing prevalence of obesity, it is pos-
sible that multiparametric MRI will become more useful
considering transient elastography’s unreliability and
failed measurements associated with increased BMI.25
Table 3 Break-even cost of multiparametric MRI when
used as an adjunct to transient elastography
Multiparametric
MRI failure rate
Transient elastography
failure rate
12% 18% 35% 50%
2.5% £654 £638 £581 £543
5% £638 £617 £567 £529
10% £604 £585 £537 £501
Table 4 Break-even cost of multiparametric MRI when
used as a replacement for transient elastography
Multiparametric
MRI failure rate
Transient elastography failure rate
12% 18% 35% 50%
2.5% £159 £221 £248 £306
5% £148 £210 £237 £294
10% £145 £187 £214 £271
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Moreover, it has been observed that the rate of uninter-
pretable results with transient elastography (due to
fewer than 10 valid measurements) is 9.6%, a value that
could be an underestimation due to potential under-
reporting.28 The relationship between BMI and the
prevalence of each stage of ﬁbrosis has not been quanti-
ﬁed, limiting any assessment of how the increased
failure rate associated with obesity affects the diagnostic
accuracy.
Controversy remains regarding the optimal cut-off
values to diagnose advanced ﬁbrosis using transient elas-
tography as the cut-off values differ across aetiologies.
This leads to variation in the interpretation of transient
elastography results.26 Initial ﬁndings suggest that multi-
parametric MRI can quantify the severity of liver
disease.27 This has implications in the monitoring and
evaluation of liver disease progression. Currently,
repeated liver biopsies are necessary to assess the stage
liver disease. From a patient and payers’ perspective, it
would be preferable that the progression of liver disease
be evaluated by a non-invasive method capable of asses-
sing the stage of the disease rather than by an invasive
and more costly liver biopsy. Since increasing disease
activity may also occur in patients with simple steatosis,
all patients with NAFLD should undergo periodic
disease progression assessment with lifestyle modiﬁcation
advice if appropriate.9 The value of transient elastogra-
phy in detecting early stages of liver disease is limited.
Results of patients with low-stage grades of ﬁbrosis (F<2)
have been associated with signiﬁcantly reduced reprodu-
cibility when compared with those of patients with
marked ﬁbrosis.9 30
The current decision analytic model aims to compare
only the diagnostic pathways for patients presenting with
suspected NAFLD. It does not consider the conse-
quences of any diagnosis, either correct or incorrect, or
failures to diagnose, with subsequent short-term and
long-term disease progression and associated treatment
outcomes. Patients with suspected NAFLD whose tests
are within the normal range with either transient elasto-
graphy or multiparametric MRI should subsequently be
retested within a period of 1–2 years in order to capture
any possible disease progression. The model does not
follow the progression of liver disease in individuals.
Rather, it presumes that the prevalence of the various
levels of ﬁbrosis in the population presenting with sus-
pected fatty liver disease, and associated diagnostic out-
comes, remain broadly the same whether patients be
new or returning. A more comprehensive model could
be developed to consider the longerterm progression of
liver disease in individuals combined with the treatment
outcomes associated with the diagnoses. This would
need considerably more evidence, and the HTA was
unable to identify robust cost and quality-adjusted life
year estimates or data on treatment effectiveness to
inform such a model.28 Future research should attempt
to address the shortcomings of currently available evi-
dence for this patient population. Other non-invasive
techniques are emerging such as MR elastography,
which uses a vibration source to generate low-frequency
mechanical waves in tissue.31–33 The wave information is
processed allowing the quantitative assessment of the
mechanical properties of tissue. The purpose of the
current study was to evaluate the inclusion of multipara-
metric MRI in current diagnostic pathways for patients
presenting with suspected NAFLD. MR elastography may
be a valuable addition to currently used techniques and
should be evaluated in further studies.
This model presumes that patients would not deviate
from the best practice guidelines for diagnostic path-
ways.14 However, in practice, diagnosis and treatment ini-
tiation is often solely based on clinical judgement
without biopsy. A recent survey observed that fewer than
25% of participating specialists performed liver biopsies
to diagnose NASH, which diverges from guidelines and
may leave NASH underdiagnosed in gastroenterology
and hepatology clinics.34
Based on current practice, the reference standard for
this model was liver biopsy, which is still regarded as the
reference for differentiating steatosis from NASH, for
staging hepatic ﬁbrosis and for identifying NAFLD in
patients with other chronic liver disease.35 However, this
is an imperfect reference standard and has recently been
considered that liver biopsy is not a suitable test for moni-
toring responses to therapy or for following disease pro-
gression.36 A UK national audit found that samples were
insufﬁcient for diagnosis in 71 (2.04%) of 3472 cases.37
Inadequate liver biopsies in which a focal lesion was
present at imaging occurred in 82 (7.1%) of 1162 biop-
sies and in 37 (1.7%) of 2155 liver biopsies where a focal
lesion was not present.37 The risk of excessive bleeding is
about 1 in 500 to 1 in 1000 and the risk of death is about
1 in 10 000 to 1 in 12 000.38 Although this risk is substan-
tially lower than previous reports, it should be noted that
transient elastography and multiparametric MRI have not
been associated with any serious side effects. These
aspects should be taken into account when modelling the
long-term diagnostic pathways.
CONCLUSION
This study demonstrates that the inclusion of multipara-
metric MRI in the diagnostic pathway of NAFLD may
lead to savings to the NHS if the model presumptions
hold. Multiparametric MRI could be included either as
an adjunct to or replacement of transient elastography,
with both scenarios presenting savings compared with
the current pathway to initial fatty liver diagnosis. In our
model, the use of multiparametric MRI as an adjunct to
transient elastography is predicted to more than halve
the number of biopsies required. It is important to gen-
erate additional high-quality clinical evidence and cost
data to develop the model further, and test its predic-
tions. Current results suggest investment in evidence
generation would have value. If these studies show that
multiparametric MRI is able to match the diagnostic
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accuracy of liver biopsy to quantify disease progression,
then there is the potential for it to replace biopsy for
the diagnosis of liver ﬁbrosis, with signiﬁcant cost
savings to the healthcare provider.
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